Archive — US — techcrunch
Startup Battlefield company SpotitEarly trained dogs and AI to sniff out commoncancers
SpotitEarly, a biotech startup featured in Startup Battlefield at TechCrunch Disrupt 2025, is developing an innovative at-home cancer screening test that combines trained dogs' remarkable sense of smell with AI. This system analyses breath samples to detect early signs of common cancers, boasting 94% accuracy and expected to cost around $250 for consumers, aiming to provide affordable cancer screening options.
Key points
- SpotitEarly developed a unique cancer screening test utilizing the smell ability of trained dogs combined with AI.
- The technology focuses on analyzing human breath to detect precursors of common cancers.
- Recent clinical studies show the method has a 94% accuracy rate for identifying early-stage cancers.
- Users collect breath samples at home and send them to SpotitEarly for, ensuring convenience and accessibility.
- The company plans to launch in the U.S. with competitive pricing compared to existing tests like Grail's Galleri.
Why it matters
- SpotitEarly's approach highlights the integration of AI with traditional methods, similar to trends predicted for 2025 in healthcare.
- Historical advancements in disease detection through animals have led to increased interest in alternative diagnostics.
- The emphasis on affordable healthcare solutions reflects the ongoing reforms in the medical industry and the demand for accessible testing.
SpotitEarly represents a promising convergence of biotechnology and animal behavior, potentially transforming cancer detection methods while addressing accessibility and affordability for consumers.